A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRaß+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC) PIDTC ?CSIDE? Protocol (Conditioning SCID Infants Diagnosed Early) PBMTC NMD 1801
What is the goal of the study?
To learn more about this study, please email the study team member listed below.
Who can participate in the study?
Please contact the study team listed below to learn more.